创新药ETF国泰（517110）盘中涨超1%，市场关注行业出海与业绩亮点

Group 1 - The core viewpoint of the article highlights the significant growth and potential of China's innovative pharmaceuticals sector, particularly in the context of international expansion and record-breaking performance in business development (BD) transactions [1] - In 2025, the total amount of BD transactions for Chinese innovative drugs reaching overseas is projected to hit $135.655 billion, with upfront payments of $7 billion and a total of 157 transactions, all marking historical highs [1] - The ongoing BD transactions validate the global competitiveness of Chinese innovative drugs, which is expected to bolster long-term investor confidence [1] Group 2 - The small nucleic acid drug sector is experiencing accelerated development, with leading companies making significant strides in new target development and treatment convenience, supported by continuously validated clinical data [1] - The increasing focus on this sector is likely to drive more licensing and merger collaborations, which could further stimulate the growth of the upstream supply chain [1] - The ETF Guotai (517110) tracks the SHS Innovative Drug Index (931409), which selects innovative pharmaceutical companies from the Shanghai, Shenzhen, and Hong Kong markets, emphasizing strong R&D capabilities and growth potential [1]